Oxford Cannabinoid Technologies was established by Kingsley Capital Partners to finance a £10m research programme at Oxford University into medical cannabis. The programme will support eight university scientists investigating medical applications across pain, cancer and inflammatory disease. The company's core role is sponsoring laboratory research aimed at developing cannabinoid-based therapies. Funding is provided as venture capital from Kingsley, which set up the company to underwrite the work. The initiative positions the company as a research sponsor and potential developer of therapeutic candidates in partnership with Oxford. Kingsley is described in the article as a private equity business based in London and its managing partner, Neil Mahapatra, framed the project as targeting innovative therapies to help millions of patients.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2017